Sionna Therapeutics (NASDAQ:SION) Reaches New 1-Year Low on Disappointing Earnings

Sionna Therapeutics, Inc. (NASDAQ:SION) shares reached a new 52-week low during trading on Friday after the company announced weaker than expected quarterly earnings. The company traded as low as $12.46 and last traded at $13.04, with a volume of 30317 shares. The stock had previously closed at $13.88.

The company reported ($3.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.68) by ($0.70).

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on SION shares. Stifel Nicolaus started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a “buy” rating and a $32.00 target price on the stock. Guggenheim started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, TD Cowen started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a “buy” rating on the stock.

Sionna Therapeutics Stock Down 1.4 %

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.